Spexis Announces Changes to the Executive Committee
01 nov. 2023 02h20 HE
|
Spexis AG
Spexis Announces Changes to the Executive Committee
Spexis provides business update and announces financial results for the first half of 2023
29 sept. 2023 01h30 HE
|
Spexis AG
Spexis provides business update and announces financial results for the first half of 2023
Spexis announces the appointment of Gonçalo Bernardes, Ph.D., as acting Head of Chemical Biology
28 sept. 2023 01h30 HE
|
Spexis AG
Spexis announces the appointment of Gonçalo Bernardes, Ph.D., as acting Head of Chemical Biology
Spexis announces engagement with Maxim Group LLC as M&A advisor to support evaluation of strategic transactions
30 juin 2023 01h15 HE
|
Spexis AG
Ad hoc announcement pursuant to Art. 53 LR ALLSCHWIL, Switzerland, June 29, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and...
Spexis provides business update and announces financial results for the full year 2022
30 mai 2023 01h15 HE
|
Spexis AG
Ad hoc announcement pursuant to Art. 53 LR USD 4.5 million capital commitment from SPRIM Global Investments to enable initiation of ColiFin® COPILOT study; first patient dosing expected in...
Spexis announces closing of capital commitment of USD 4.5 million from SPRIM Global Investments (SGI) to enable initiation of ColiFin® Phase 3 study
18 avr. 2023 02h23 HE
|
Spexis AG
Ad hoc announcement pursuant to Art. 53 LR Funding to enable immediate initiation of the COPILOT study, the first of two Phase 3 ColiFin® studies; first-patient-in expected in June 2023Commitment...
EnBiotix, Inc. Closes $11M Pre-Merger Financing
29 déc. 2021 02h30 HE
|
EnBiotix, Inc.
BOSTON, Dec. 29, 2021 (GLOBE NEWSWIRE) -- EnBiotix, Inc., a rare disease company currently focused on chronic respiratory disorders, today announced the closing of an $11M pre-merger, convertible...